• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 17, 2013

View Archived Issues

Infinity's Perkins Finds Success Through Working the Options

When Adelene Perkins looks back on her career, starting with a B.S. in chemical engineering from Villanova University, through her current position as president and CEO of Infinity Pharmaceuticals Inc., one theme that emerges is "optionality," a philosophy of continuously developing multiple viable options and paths at the same time. Read More

Framing the Problem: Scaffold Key to Bispecifics, Sutro Says

This week's deal between Affimed Therapeutics AG and Johnson & Johnson put the bispecific antibody space in the headlines once again, as the field took another step toward becoming as hot as antibody-drug conjugates, said Jeremy Bender, chief business officer of Sutro Biopharma Inc., which made news in December via its deal with Celgene Corp. Read More

Bacteria Can Acquire DNA in a Meiosis-Like Transfer

Scientists have discovered that some bacteria have found a way to combine the advantages of sexual and asexual reproduction, using a process that its discoverers have termed "distributive conjugal transfer" to gain some of the advantages of sexual production while avoiding its drawbacks. Read More

Ariana's Statistical Algorithms to Separate Signal from Noise

Ariana Pharma SA is developing software to guide the selection of personalized cancer care as part of a clinical trial in patients which, the study investigators claim, will be the first to offer all participants a treatment regimen based on their individual DNA, RNA and microRNA profiles. Read More

IMI 2 to Launch in January; $4.5B for Vaccines, Drugs

LONDON – The European Union said the second phase of the Innovative Medicines Initiative (IMI 2) will get under way in January 2014 with a budget of €3.45 billion (US$4.5 billion) to be devoted to the development of vaccines and treatments for a range of chronic and degenerative diseases. Read More

Financings Roundup

• Immunomic Therapeutics Inc., of Hershey, Pa., said it completed a $3 million debt financing round in advance of a Series B round planned for later this year. Read More

Stock Movers

Read More

Other News To Note

• Biovest International Inc., of Tampa, Fla., said it emerged from Chapter 11 reorganization, formally completing its restructuring and recapitalization strategy, with its plan of reorganization becoming effective July 9. Read More

Clinic Roundup

• Oncogenex Pharmaceuticals Inc., of Bothell, Wash., said enrollment was completed in Borealis-1, a company-sponsored Phase II trial testing heat-shock protein 27 inhibitor OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer. About 180 patients were recruited into the study. Read More

Pharma: Other News To Note

• Merck KGaA, of Darmstadt, Germany, said its Merck Serono unit signed an agreement to collaborate with Life Technologies Corp., of Carlsbad, Calif., for current and future companion diagnostics projects. Read More

Pharma: Clinic Roundup

• Baxter International Inc., of Deerfield, Ill., presented data at the Alzheimer's Association International Conference in Boston from the Phase III Gammaglobulin Alzheimer's Partnership study showing that, as previously disclosed, the study did not meet its co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer's disease. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe